

Synonym

IL13RA2,CD213A2,CT19,IL-13R,IL13BP

Source

FITC-Labeled Human IL-13 R alpha 2, His Tag (IL2-HF2H3) is expressed from human 293 cells (HEK293). It contains AA Asp 27 - Arg 343 (Accession # Q14627-1). It is the FITC labeled form of Human IL-13 R alpha 2, His Tag (IL2-H52H5).

Predicted N-terminus: Asp 27

Molecular Characterization

IL-13RA2(Asp 27 - Arg 343) Q14627-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 39.0 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Conjugate

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

Labeling

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

Protein Ratio

The FITC to protein molar ratio is 1-3.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE




FITC-Labeled Human IL-13 R alpha 2 Protein, His Tag

Catalog # IL2-HF2H3



FITC-Labeled Human IL-13 R alpha 2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Immobilized Human IL-13, His Tag (Cat. No. IL3-H52H4) at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-13 R alpha 2, His Tag (Cat. No. IL2-HF2H3) with a linear range of 0.313-1.25 μg/mL (QC tested).

FITC-Labeled Human IL-13 R alpha 2, His Tag ELISA 0.1 µg of Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 per well 10000-8000 Fluorescence in RFU 6000 EC50=0.11 μg/mL 4000 2000 0.01 0.1 1 10 100

Immobilized Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-13 R alpha 2, His Tag (Cat. No. IL2-HF2H3) with a linear range of 0.078-0.313 µg/mL (QC tested).

FITC-Labeled Human IL-13 R alpha 2, His Tag Conc. (μg/mL)

Background

Interleukin-13 receptor subunit alpha-2 is also known as IL13Rα2, IL13Ra2 cluster of differentiation 213A2, CD213A2, CT19, IL-13R, IL13BP, and is a membrane bound protein that in humans is encoded by the IL13RA2 gene. IL13Rα2 is closely related to IL13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however able to regulate the effects of both IL13 and IL4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13. IL13Rα2 is a component of the cell surface receptors, however, the majority exists in intracellular pools and in soluble form, and thus plays an opposite role as a potent IL13 antagonist compared with IL13Ra1. It also functions as an inhibitor of IL4-dependent pathway probably through the physical interaction between the short intracellular domain of and cytoplasmic domain of IL13Rα2 and the IL4Rα chain. In spite of the failed STAT signaling function, IL13Rα2 dose induce TGF-beta production and fibrosis. Additionally, IL13Rα2has been reported to be abundantly and specifically overexpressed in glioblastoma multiforme.

Clinical and Translational Updates

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.